Kwivik Welcomes Hon. Mike Farhat as Chairman of Strategic Advisory Board
August 10, 2021
Frisco, Texas, August 10, 2021 – Kwivik Therapeutics Inc (“Kwivik”), a medtech developer of disruptive technologies for respiratory and emergency medical markets today welcomed Hon. Mike Farhat as Chairman of its Strategic Advisory Board.
Hon. Mike Farhat is a prolific and respected business leader, humanitarian and philanthropist. As Chairman of United States Global Partners Hon. Farhat has presided over billions of dollars in development and trade projects in multiple industries globally, including medical and healthcare, hospitality, banking, aviation, public safety, finance and large-scale public-private sector development projects.
Kwivik Therapeutics Receives Market Clearance for O2Ventilate in India
July 7, 2021
Frisco, Texas, July 7, 2021 – Kwivik Therapeutics Inc (“Kwivik”), a medtech developer of disruptive technologies for respiratory and emergency medical markets today announced the Company has received market clearance for its O2Ventilate product from the Ministry of Health in India.
O2Ventilate is a Manual Emergency Ventilator system intended for the emergency, non-invasive ventilation of children and adults. The device does not require any battery or power to operate, is portable and ideal for use prior to or during transportation to the hospital or ER. Beyond its evident use in COVID19 emergencies, O2Ventilate is used in any situation with a need to deliver positive pressure oxygenated ventilation to any patient with insufficient or ineffective breaths.
Kwivik Listed on Fundable
April 15, 2021
Kwivik Therapeutics Inc was listed on Fundable, a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.
To view the Company's profile on Fundable, please click here...
CES: Consumerization Will Be The Future of Digital Health
Jan 2021 Crunchbase News
“The consumerization of health and the need for a better experience. Post-COVID has emphasized that in simplifying the experience and making it consumer-first.” Lynne O’Keefe, founder and Managing Partner at Define Ventures.
"The risk of going into the hospital is high today, and people are afraid. As a result, I see a lot of direct-to-consumer and at-home products." Sydney Thomas, principal at Precursor Ventures.
“COVID created some really long-lasting changes in everything. I actually don’t mind.
A number of companies I did last year were being supported by the tailwinds of COVID. I am going to continue to invest in those companies." Sydney Thomas, principal at Precursor Ventures, on COVID as a sustainable business opportunity. Read more...
Intel Chairman Planning Up to $1 Billion Health-Tech SPAC IPO
Intel Corp. Chairman Omar Ishrak is planning to raise funds for a blank-check firm targeting deals in the health technology sector, according to people with knowledge of the matter.
Ishrak, who previously ran medical device giant Medtronic Plc, could file public registration documents with the U.S. Securities and Exchange Commission as soon as Tuesday, the people said, asking not to be identified because the information is private. Ishrak is targeting to raise about $750 million to $1 billion for the special purpose acquisition company, or SPAC, they said.
Goldman Sachs Group Inc. is leading preparations for the initial public offering, the people said. Hedge fund manager Joshua Fink, who is the son of BlackRock Inc.’s Larry Fink, and Medtronic executive Jean Nehme will have senior roles at the blank-check company, the people said. Ishrak is poised to be chairman, they said.
Kwivik Therapeutics Partners with EirMed to Accelerate Product Commercialization
Kwivik Therapeutics Inc (“Kwivik”), a medtech developer of disruptive technologies for respiratory and emergency medical markets today announced the Company has partnered with EirMed to accelerate commercialization of some of its therapeutics product lines.
Kwivik has developed a pipeline of novel products for certain respiratory, emergency medical, asthma, migraine/cluster headache, wound care and skin care markets, with a combined market size exceeding a remarkable $750 Billion. These products are tracked, monitored and enhanced with Kwivik’s proprietary, cloud-based Mobile, IoT and AI technologies, with the goal of improving medical outcomes and saving lives – more efficiently and effectively than ever before.
“We are excited to be working with EirMed as we enter a growth phase in our business,” said Julian Ross, CEO of Kwivik Therapeutics. “EirMed is a fine organization and will significantly expand our capacity and depth with their infrastructure, design, engineering, manufacturing, quality control, and regulatory compliance capabilities.”
Largest players in MedTech industry embrace artificial intelligence
According to GlobalData forecasts, the market for artificial intelligence (AI)/machine learning (ML) platforms will reach $52B in 2024, up from $29B in 2019. The Covid-19 pandemic has triggered a rapid implementation of new technologies in the medical technology industry. Consequently, the MedTech industry’s biggest players, such as GE Healthcare, Medtronic, and Philips are some of the biggest investors in AI and ML. Implementing AI and ML into the traditionally conservative medical technology field has the potential to improve the current methods of diagnosing, managing, and treating numerous diseases and health issues.
Furthermore, with big data becoming more and more assessable and manageable, it is now possible to effectively analyse, process, and find new patterns in medical data, especially when combined with ML algorithms.